AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
AIM ImmunoTech (NYSE American: AIM) announced the publication of a significant peer-reviewed article in the Journal for ImmunoTherapy of Cancer. The research demonstrates a positive combination effect of AIM's drug Ampligen when used with interferon-alpha on tumor growth and patient survival.
The study reveals that systemic chemokine modulation can overcome PD-1 resistance in cold tumors, highlighting that intratumoral cytotoxic t-lymphocyte accumulation is the crucial factor in immune checkpoint inhibitor effectiveness. The findings suggest promising potential for tumor microenvironment reprogramming strategies in cancer treatment.
AIM ImmunoTech (NYSE American: AIM) ha annunciato la pubblicazione di un importante articolo peer-reviewed sul Journal for ImmunoTherapy of Cancer. La ricerca dimostra un effetto combinato positivo del farmaco Ampligen di AIM, utilizzato in associazione con l’interferone-alfa, sulla crescita dei tumori e sulla sopravvivenza dei pazienti.
Lo studio rivela che la modulazione sistemica delle chemochinè può superare la resistenza al PD-1 nei tumori freddi, evidenziando che l’accumulo intratumorale di linfociti T citotossici è il fattore cruciale per l’efficacia degli inibitori del checkpoint immunitario. I risultati suggeriscono un potenziale promettente per le strategie di riprogrammazione del microambiente tumorale nel trattamento del cancro.
AIM ImmunoTech (NYSE American: AIM) anunció la publicación de un importante artículo revisado por pares en Journal for ImmunoTherapy of Cancer. La investigación demuestra un efecto de combinación positivo del fármaco Ampligen de AIM cuando se usa con interferón-alfa sobre el crecimiento tumoral y la supervivencia del paciente.
El estudio revela que la modulación sistémica de quimocinas puede superar la resistencia a PD-1 en tumores fríos, destacando que la acumulación intratumoral de linfocitos T citotóxicos es el factor crucial para la efectividad de los inhibidores de puntos de control inmunitarios. Los hallazgos sugieren un prometedor potencial para estrategias de reprogramación del microambiente tumoral en el tratamiento del cáncer.
AIM ImmunoTech (NYSE American: AIM)은 Journal for ImmunoTherapy of Cancer에 실린 중요한 동료 심사 논문의 발표를 발표했다. 연구는 AIM의 약물 Ampligen을 인터페론-알파와 함께 사용할 때 종양 성장과 환자 생존에 긍정적인 결합 효과가 있음을 보여준다.
연구에 따르면 전신 케모카인(modulation) 조절은 냉성 종양에서 PD-1 저항을 극복할 수 있으며, 종양 내 사이토톡식 T 림프구 축적이 면역 체크포인트 억제제의 효과에 결정적 요인임을 강조한다. 이 발견은 암 치료에서 종양 미세환경 재프로그래밍 전략의 유망한 가능성을 시사한다.
AIM ImmunoTech (NYSE American: AIM) a annoncé la publication d’un article évalué par les pairs dans le Journal for ImmunoTherapy of Cancer. La recherche démontre un effet de combinaison positif du médicament Ampligen d’AIM lorsqu’il est utilisé avec l’interféron-alpha sur la croissance des tumeurs et la survie des patients.
L’étude révèle que la modulation systémique des chimokines peut surmonter la résistance au PD-1 dans les tumeurs froides, en soulignant que l’accumulation des lymphocytes T cytotoxiques intratumoraux est le facteur clé de l’efficacité des inhibiteurs des checkpoints immunitaires. Les résultats suggèrent un potentiel prometteur pour les stratégies de remodélisation du microenvironnement tumoral dans le traitement du cancer.
AIM ImmunoTech (NYSE American: AIM) gab bekannt, dass eine bedeutende von Fachleuten begutachtete Studie im Journal for ImmunoTherapy of Cancer veröffentlicht wurde. Die Forschung zeigt eine positive Kombinationswirkung des AIM-Medikaments Ampligen, das in Verbindung mit Interferon-Alpha die Tumorwachstumsraten und das Überleben der Patienten beeinflusst.
Die Studie belegt, dass eine systemische Modulation von Chemokinen die PD-1-Resistenz bei kalten Tumoren überwinden kann und hebt hervor, dass die intratumorale Anhäufung zytotoxischer T-Lymphozyten der entscheidende Faktor für die Wirksamkeit von Immun-Checkpoint-Inhibitoren ist. Die Ergebnisse deuten auf ein vielversprechendes Potenzial für Strategien zur Umprogrammierung des Tumormikromilieus in der Krebstherapie hin.
AIM ImmunoTech (NYSE American: AIM) أعلنت عن نشر مقالة مراجعة من قبل أقران في مجلة Journal for ImmunoTherapy of Cancer. تُظهر الدراسة تأثيرًا تآزريًا إيجابيًا لعقار Ampligen من AIM عند استخدامه مع الإنترفيرون-ألفا على نمو الورم وبقاء المريض على قيد الحياة.
تكشف الدراسة أن تعديل مركزي لمشغّلات الكيميائيات يمكن أن يتجاوز مقاومة PD-1 في الأورام الباردة، مع التأكيد أن تراكم الخلايا اللمفاوية القاتلة داخل الورم هو العامل الحاسم في فعالية مثبطات نقاط التفتيش المناعي. تشير النتائج إلى إمكانية واعدة لاستراتيجيات إعادة برمجة بيئة الورم الدقيقة في علاج السرطان.
AIM ImmunoTech (NYSE American: AIM) 宣布在《癌症免疫治疗杂志》（Journal for ImmunoTherapy of Cancer）发表了一篇重要的同行评审文章。研究显示在将 AIM 的药物 Ampligen 与干扰素α 联用时，对肿瘤生长和患者存活具有
研究显示，全身性趋化因子调控可以克服冷肿瘤中的 PD-1 抗性，强调 肿瘤内细胞毒性 T 淋巴细胞的积累 是免疫检查点抑制剂有效性的关键因素。发现表明，在癌症治疗中，肿瘤微环境重新编程策略具有潜在前景。
- Publication in prestigious Journal for ImmunoTherapy of Cancer validates research
- Positive combination effect demonstrated between Ampligen and interferon-alpha
- Research suggests broad therapeutic potential for cancer treatment
- None.
New peer-reviewed article appears in the Journal for ImmunoTherapy of Cancer
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM’s drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival.
The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad therapeutic potential of tumor microenvironment reprogramming strategies.
The article, titled "Synergy between TLR3-ligand and IFN-α in the transient sensitization of ‘Cold’ tumors to PD-1 blockade and the induction of systemic immunity," was published in JITC on September 18.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ
What did AIM ImmunoTech's new research publication reveal about Ampligen?
Where was AIM ImmunoTech's new cancer research published?
What is the significance of AIM ImmunoTech's tumor microenvironment findings?
How does AIM's Ampligen combination therapy work against cold tumors?
